Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression

Science Translational Medicine

Volumn 4, Issue 148, 2012, Pages

  Lauring, Brett ^a   Taggart, Andrew K P ^a   Tata, James R ^a   Dunbar, Richard ^b   Caro, Luzelena ^a   Cheng, Kang ^a   Chin, Jayne ^a   Colletti, Steven L ^a   Cote, Josee ^a   Khalilieh, Sauzanne ^a   Liu, Jiajun ^a   Luo, Wen Lin ^a   MacLean, Alexandra A ^a   Peterson, Laurence B ^a   Polis, Adam B ^a   Sirah, Waheeda ^a   Wu, Tsuei Ju ^a   Liu, Xuan ^a   Jin, Lan ^a   Wu, Kenneth ^a   Boatman, P Douglas ^c   Semple, Graeme ^c   Behan, Dominic P ^c   Connolly, Daniel T ^c   Lai, Eseng ^a   Wagner, John A ^a   Wright, Samuel D ^a   Cuffie, Cynthia ^a   Mitchel, Yale B ^a   Rader, Daniel J ^b   Paolini, John F ^a   Waters, M Gerard ^a   Plump, Andrew ^a,d   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ARENA PHARMACEUTICALS   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLISOXAZOLE 5 CARBOXYLIC ACID; ACIFRAN; ACIPIMOX; ANTILIPEMIC AGENT; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GPR109A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 1903; NICOTINIC ACID; PLACEBO; RECEPTOR PROTEIN; SCH 900271; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY ACID SYNTHESIS; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; LIPID DIET; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; HUMANS; LIPOLYSIS; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; NIACIN; PYRAZOLES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 84865330824     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003877     Document Type: Article

References (47)

1. L. A. Carlson, Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94-114 (2005).
2. A. Gille, E. T. Bodor, K. Ahmed, S. Offermanns, Nicotinic acid: Pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48, 79-106 (2008).
3. R. P. Eaton, M. Berman, D. Steinberg, Kinetic studies of plasma free fatty acid and triglyceride metabolism in man. J. Clin. Invest. 48, 1560-1579 (1969).
4. L. A. Carlson, Studies on the incorporation of injected palmitic acid-I-C into liver and plasma lipids in man. Acta Soc. Med. Ups. 65, 85-90 (1960).
5. L. A. Carlson, L. Oro, The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med. Scand. 172, 641-645 (1962).
6. S. M. Grundy, H. Y. Mok, L. Zech, M. Berman, Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22, 24-36 (1981).
7. J. Hanson, A. Gille, S. Zwykiel, M. Lukasova, B. E. Clausen, K. Ahmed, S. Tunaru, A. Wirth, S. Offermanns, Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 120, 2910-2919 (2010).
8. M. Hernandez, S. D. Wright, T. Q. Cai, Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem. Biophys. Res. Commun. 355, 1075-1080 (2007).
9. J. W. van der Hoorn, W. de Haan, J. F. Berbee, L. M. Havekes, J. W. Jukema, P. C. Rensen, H. M. Princen, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol. 28, 2016-2022 (2008).
10. L. H. Zhang, V. S. Kamanna, S. H. Ganji, X. M. Xiong, M. L. Kashyap, Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. J. Lipid Res. 53, 941-950 (2012).
11. S. Tunaru, J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, S. Offermanns, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9, 352-355 (2003).
12. Z. Benyó, A. Gille, C. L. Bennett, B. E. Clausen, S. Offermanns, Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharmacol. 70, 1844-1849 (2006).
13. J. G. Richman, M. Kanemitsu-Parks, I. Gaidarov, J. S. Cameron, P. Griffin, H. Zheng, N. C. Guerra, L. Cham, D. Maciejewski-Lenoir, D. P. Behan, D. Boatman, R. Chen, P. Skinner, P. Ornelas, M. G. Waters, S. D. Wright, G. Semple, D. T. Connolly, Nicotinic acid receptor agonists differentially activate downstream effectors. J. Biol. Chem. 282, 18028-18036 (2007).
14. M. N. Cayen, M. A. Kallai-Sanfacon, J. Dubuc, E. Greselin, D. Dvornik, Effect of AY-25,712 on fatty acid metabolism in rats. Atherosclerosis 45, 281-290 (1982).
15. A. T. Santomauro, G. Boden, M. E. Silva, D. M. Rocha, R. F. Santos, M. J. Ursich, P. G. Strassmann, B. L. Wajchenberg, Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48, 1836-1841 (1999).
16. E. Lai, M. G. Waters, J. R. Tata, W. Radziszewski, I. Perevozskaya, W. Zheng, L. Wenning, D. T. Connolly, G. Semple, A. O. Johnson-Levonas, J. A. Wagner, Y. Mitchel, J. F. Paolini, Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J. Clin. Lipidol. 2, 375-383 (2008).
17. J. C. LaRosa, V. T. Miller, K. D. Edwards, M. R. DeBovis, D. B. Stoy, Acifran: A double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients. Artery 14, 338-350 (1987).
18. D. B. Hunninghake, K. D. Edwards, G. S. Sopko, R. L. Tosiello, Controlled trial of acifran in type II hyperlipoproteinemia. Clin. Pharmacol. Ther. 38, 313-317 (1985).
19. J. K. Jung, B. R. Johnson, T. Duong, M. Decaire, J. Uy, T. Gharbaoui, P. D. Boatman, C. R. Sage, R. Chen, J. G. Richman, D. T. Connolly, G. Semple, Analogues of acifran: Agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J. Med. Chem. 50, 1445-1448 (2007).
20. M. J. Ball, M. Vella, J. P. Rechlass, D. B. Jones, C. Stirling, J. I. Mann, D. Galton, Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial. Eur. J. Clin. Pharmacol. 31, 201-204 (1986).
21. C. W. Barlow, E. R. Soicher, D. Jankelow, D. P. Myburgh, Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia. S. Afr. Med. J. 77, 504-505 (1990).
22. P. Davidoff, F. Ruiz, M. A. Varas, M. García de los Ríos, M. A. Silva, G. González, J. C. Tapia, Acipimox in primary hyperlipidemias: Safety and efficacy evaluated in six months. Rev. Med. Chil. 119, 1140-1146 (1991).
23. P. M. Davoren, W. Kelly, F. A. Gries, A. Hubinger, C. Whately-Smith, K. G. Alberti, Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus. Metabolism 47, 250-256 (1998).
24. J. D. Dean, S. McCarthy, D. J. Betteridge, C. Whately-Smith, J. Powell, D. R. Owens, The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia. Diabet. Med. 9, 611-615 (1992).
25. G. R. Fulcher, C. Catalano, M. Walker, M. Farrer, J. Thow, C. R. Whately-Smith, K. G. Alberti, A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet. Med. 9, 908-914 (1992).
26. P. Tornvall, G. Walldius, A comparison between nicotinic acid and acipimox in hypertriglyceridaemia - Effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J. Intern. Med. 230, 415-421 (1991).
27. M. J. O'Kane, T. R. Trinick, M. B. Tynan, E. R. Trimble, D. P. Nicholls, A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br. J. Clin. Pharmacol. 33, 451-453 (1992).
28. M. Lukasova, C. Malaval, A. Gille, J. Kero, S. Offermanns, Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121, 1163-1173 (2011).
29. G. Semple, P. J. Skinner, T. Gharbaoui, Y. J. Shin, J. K. Jung, M. C. Cherrier, P. J. Webb, S. Y. Tamura, P. D. Boatman, C. R. Sage, T. O. Schrader, R. Chen, S. L. Colletti, J. R. Tata, M. G. Waters, K. Cheng, A. K. Taggart, T. Q. Cai, E. Carballo-Jane, D. P. Behan, D. T. Connolly, J. G. Richman, 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 51, 5101-5108 (2011).
30. P. D. Boatman, J. G. Richman, G. Semple, Nicotinic acid receptor agonists. J. Med. Chem. 51, 7653-7662 (2008).
31. P. D. Boatman, B. Lauring, T. O. Schrader, M. Kasem, B. R. Johnson, P. Skinner, J. K. Jung, J. Xu, M. C. Cherrier, P. J. Webb, G. Semple, C. R. Sage, J. Knudsen, R. Chen, W. L. Luo, L. Caro, J. Cote, E. Lai, J. Wagner, A. K. Taggart, E. Cabrallo-Jane, M. Hammond, S. L. Colletti, J. R. Tata, D. T. Connolly, M. G. Waters, J. G. Richman, (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3- diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): A potent GPR109a agonist that lowers free fatty acids in humans. J. Med. Chem. 55, 3644-3666 (2012).
32. D. Maciejewski-Lenoir, J. G. Richman, Y. Hakak, I. Gaidarov, D. P. Behan, D. T. Connolly, Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol. 126, 2637-2646 (2006).
33. D. Maccubbin, H. E. Bays, A. G. Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, O. Kuznetsova, C. M. Sisk, R. C. Pasternak, J. F. Paolini, Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int. J. Clin. Pract. 62, 1959-1970 (2008).
34. V. S. Kamanna, S. H. Ganji, M. L. Kashyap, Niacin: An old drug rejuvenated. Curr. Atheroscler. Rep. 11, 45-51 (2009).
35. B. J. Wu, L. Yan, F. Charlton, P. Witting, P. J. Barter, K. A. Rye, Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30, 968-975 (2010).
36. P. L. Canner, K. G. Berge, N. K. Wenger, J. Stamler, L. Friedman, R. J. Prineas, W. Friedewald, Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
37. A. G. Olsson, Recent advances in preventing cardiovascular disorders by managing lipid levels. F1000 Med. Rep. 2, 66 (2010).
38. H. E. Bays, C. Ballantyne, What's the deal with niacin development: Is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr. Opin. Lipidol. 20, 467-476 (2009).
39. Z. Benyó, A. Gille, J. Kero, M. Csiky, M. C. Suchá nková, R. M. Nüsing, A. Moers, K. Pfeffer, S. Offermanns, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115, 3634-3640 (2005).
40. G. J. de Grooth, A. H. Klerkx, E. S. Stroes, A. F. Stalenhoef, J. J. Kastelein, J. A. Kuivenhoven, A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45, 1967-1974 (2004).
41. S. H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, M. L. Kashyap, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid Res. 45, 1835-1845 (2004).
42. C. Hernandez, M. Molusky, Y. Li, S. Li, J. D. Lin, Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid. Cell Metab. 12, 411-419 (2010).
43. F. Y. Jin, V. S. Kamanna, M. L. Kashyap, Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 17, 2020-2028 (1997).
44. S. Lamon-Fava, M. R. Diffenderfer, P. H. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, E. J. Schaefer, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28, 1672-1678 (2008).
45. W. Wang, A. Basinger, R. A. Neese, B. Shane, S. A. Myong, M. Christiansen, M. K. Hellerstein, Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physiol. Endocrinol. Metab. 280, E540-E547 (2001).
46. O. Miettinen, M. Nurminen, Comparative analysis of two rates. Stat. Med. 4, 213-226 (1985).
47. W. T. Friedewald, R. I. Levy, D. S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502 (1972).